Merck KGaA (FRA:MRK) Given a €94.00 Price Target by Barclays Analysts

Barclays set a €94.00 ($109.30) target price on Merck KGaA (FRA:MRK) in a research report released on Monday, Borsen Zeitung reports. The firm currently has a sell rating on the healthcare company’s stock.

A number of other research firms also recently issued reports on MRK. Sanford C. Bernstein set a €120.00 ($139.53) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Monday, January 6th. UBS Group set a €104.00 ($120.93) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, November 26th. JPMorgan Chase & Co. set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Monday, January 6th. Kepler Capital Markets set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the stock a buy rating in a research report on Wednesday, November 13th. Finally, HSBC set a €96.00 ($111.63) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of €105.47 ($122.64).

FRA MRK opened at €119.05 ($138.43) on Monday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72). The company’s fifty day moving average price is €108.08 and its two-hundred day moving average price is €102.22.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.